Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAXIBACUMAB vs BEYFORTUS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Raxibacumab is a monoclonal antibody that binds to the protective antigen (PA) component of Bacillus anthracis toxins, preventing PA from binding to host cell receptors and thereby inhibiting the intracellular entry of lethal factor and edema factor. This neutralizes the lethal and edema toxins, reducing pathogenicity.
BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody that binds to the prefusion conformation of the respiratory syncytial virus (RSV) F protein, inhibiting viral entry into host cells by blocking the fusion of the viral envelope with the host cell membrane.
Inhalational anthrax: Treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs,Inhalational anthrax prophylaxis: Prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate
Prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants entering their first RSV season, and in children up to 24 months of age who remain vulnerable through their second RSV season.
Single intravenous dose of 40 mg/kg administered over 30 minutes.
Not applicable; BEYFORTUS (nirsevimab) is indicated for prevention of respiratory syncytial virus lower respiratory tract disease in neonates and infants. No adult dose exists.
Terminal elimination half-life approximately 12-24 hours (mean ~18 hours) in patients with normal renal function; half-life extends in renal impairment.
Terminal elimination half-life is approximately 26.8 days in infants, supporting season-long protection after a single dose.
Monoclonal antibodies are generally degraded into small peptides and amino acids via catabolic pathways, similar to endogenous immunoglobulins. Raxibacumab metabolism is not mediated by hepatic CYP450 enzymes.
Nirsevimab is degraded via catabolic pathways into small peptides and amino acids.
Primarily renal excretion as intact protein; >90% of administered dose recovered in urine over 48 hours.
Beyfortus (nirsevimab) is eliminated primarily via catabolism to small peptides and amino acids. No specific data on renal or biliary excretion; expected to undergo proteolytic degradation with minimal renal or fecal elimination of intact drug.
Negligible protein binding (<1% bound) as a monoclonal antibody.
Protein binding is approximately 99.5%, primarily to albumin.
Volume of distribution approximately 0.15 L/kg, indicating limited extravascular distribution consistent with a large protein.
Volume of distribution is approximately 4.5 L in infants (mean Vd ≈ 0.3 L/kg), indicating distribution primarily in plasma and interstitial fluid.
Intravenous: 100%; Subcutaneous: Approximately 60-70% (mean ~65%).
Bioavailability after intramuscular injection is approximately 70-80% (absolute bioavailability not established; relative to IV data).
No dosage adjustment required for any degree of renal impairment including end-stage renal disease.
No dosage adjustment required for renal impairment; nirsevimab is a monoclonal antibody not renally cleared.
No dosage adjustment required for any degree of hepatic impairment.
No dosage adjustment required for hepatic impairment; nirsevimab is a monoclonal antibody not hepatically metabolized.
Safety and efficacy in pediatric patients have not been established.
Neonates and infants weighing <5 kg: 50 mg intramuscular (IM) single dose; infants weighing ≥5 kg: 100 mg IM single dose. Administer during RSV season.
No specific dosage adjustment recommended; clinical studies included limited number of patients aged 65 and older.
Not indicated for geriatric population; no dosing recommendations available.
None.
No black box warning.
Hypersensitivity reactions, including anaphylaxis, have been reported. Monitor patients during infusion and have appropriate medical support available.,Infusion-related reactions (e.g., urticaria, pruritus, rash) may occur. Slow or stop infusion if severe.,Interference with immune response: As a monoclonal antibody, may interfere with the immune response to anthrax vaccination. Use with caution.,Limited clinical data: Efficacy is based on animal models; clinical efficacy in humans is not established.
Hypersensitivity reactions including anaphylaxis have been reported.,Use caution in patients with thrombocytopenia or any coagulation disorder due to risk of bleeding from intramuscular injection.
None.
History of serious hypersensitivity reaction to nirsevimab or any component of the formulation.
No known food interactions. Take with or without food.
No known food interactions. BEYFORTUS is administered by intramuscular injection and does not interact with dietary components.
FDA Pregnancy Category C. Animal studies show embryotoxicity at high doses; no adequate human studies. Avoid in pregnancy unless benefit outweighs risk. First trimester: potential for teratogenicity; second and third trimesters: risk of fetal hemorrhage due to antiplatelet effect.
BEYFORTUS (nirsevimab) is a human monoclonal antibody against respiratory syncytial virus. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, no adverse developmental effects were observed in pregnant rabbits or cynomolgus monkeys at doses up to 10 times the human clinical exposure. However, because monoclonal antibodies are transported across the placenta in increasing amounts as pregnancy progresses (especially in the third trimester), potential fetal exposure may occur. Based on limited data, the risk of major birth defects and miscarriage is unknown but expected to be low due to the Ig G1 nature and lack of known teratogenic signal.
Unknown if excreted in human breast milk. M/P ratio not determined. Due to long half-life and potential for bleeding, caution advised; consider discontinuing breastfeeding during therapy.
There are no data on the presence of nirsevimab in human milk, effects on the breastfed infant, or effects on milk production. Nirsevimab is a human monoclonal antibody (Ig G1) and is expected to be excreted into human milk in small amounts due to the high molecular weight and limited transfer via the neonatal Fc receptor. The M/P ratio has not been determined. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for BEYFORTUS and any potential adverse effects on the breastfed infant from the drug or underlying condition.
No specific studies; pharmacokinetics may be altered due to increased plasma volume and renal clearance. Use lowest effective dose; consider dose reduction based on platelet count and bleeding risk.
No dosing adjustments are required for BEYFORTUS during pregnancy. Pregnancy-related physiological changes (e.g., increased plasma volume, altered renal clearance) are not expected to significantly affect the pharmacokinetics of a monoclonal antibody administered intramuscularly, as nirsevimab has a long half-life and is not renally excreted. The standard single dose of 50 mg (for infants <5 kg) or 100 mg (for infants ≥5 kg) is recommended regardless of pregnancy status.
Raxibacumab is a monoclonal antibody indicated for inhalation anthrax and prophylaxis when alternative therapies are unavailable. Administer intravenously over 2 hours and 15 minutes. Premedication with diphenhydramine is recommended to reduce infusion reactions. Monitor for anaphylaxis. Not effective for cutaneous anthrax. Use in pregnancy only if benefit outweighs risk.
BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. It is administered as a single intramuscular injection, typically 50 mg for infants <5 kg and 100 mg for infants ≥5 kg. It is not a treatment for active RSV infection. It does not interfere with live attenuated vaccines; however, administration with other injectable vaccines at different sites is acceptable. Do not administer to infants with a history of severe hypersensitivity to nirsevimab or any excipients. Efficacy has not been established in infants with a history of RSV infection.
This medication is given as an intravenous infusion for anthrax infection or prevention.,You will receive premedication to reduce the risk of allergic reactions.,Report any symptoms of allergic reaction such as hives, itching, difficulty breathing, or swelling during infusion.,This drug is not a vaccine and does not provide long-term protection.,Complete the full course of treatment as prescribed even if you feel better.
This vaccine is given as a single shot to prevent serious RSV disease in your infant.,It is not a treatment for active RSV infection; if your infant has RSV symptoms, inform the healthcare provider.,Common side effects include injection site reactions, rash, and fever. Contact your provider if these persist or worsen.,Inform the healthcare provider of any allergic reactions or bleeding disorders before administration.,Your infant can still receive other vaccines as scheduled.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAXIBACUMAB vs BEYFORTUS, answered by our medical review team.
RAXIBACUMAB is a Monoclonal Antibody that works by Raxibacumab is a monoclonal antibody that binds to the protective antigen (PA) component of Bacillus anthracis toxins, preventing PA from binding to host cell receptors and thereby inhibiting the intracellular entry of lethal factor and edema factor. This neutralizes the lethal and edema toxins, reducing pathogenicity.. BEYFORTUS is a Monoclonal Antibody for RSV Prophylaxis that works by BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody that binds to the prefusion conformation of the respiratory syncytial virus (RSV) F protein, inhibiting viral entry into host cells by blocking the fusion of the viral envelope with the host cell membrane.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAXIBACUMAB and BEYFORTUS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAXIBACUMAB is: Single intravenous dose of 40 mg/kg administered over 30 minutes.. The standard adult dose of BEYFORTUS is: Not applicable; BEYFORTUS (nirsevimab) is indicated for prevention of respiratory syncytial virus lower respiratory tract disease in neonates and infants. No adult dose exists.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAXIBACUMAB and BEYFORTUS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAXIBACUMAB is classified as Category C. FDA Pregnancy Category C. Animal studies show embryotoxicity at high doses; no adequate human studies. Avoid in pregnancy unless benefit outweighs risk. First trimester: potential . BEYFORTUS is classified as Category C. BEYFORTUS (nirsevimab) is a human monoclonal antibody against respiratory syncytial virus. There are no adequate and well-controlled studies in pregnant women. In animal reproducti. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.